Evidence regarding IL-17A promotion of tumors comes from a variety of sources, whereas evidence of tumor suppression is mostly derived from immunohistochemistry, suggesting that the heterogeneity of IL-17A assay methods or tumors may have an impact on outcomes. This evidence concerns the gene IL17A and neoplasm.